The resource for transforming liver services sits with integrated care boards, who will consider local need and the actions to progress alongside other clinical priorities.

The national team’s role has been to bring together relevant stakeholders to co-ordinate, influence and share learning to support local transformation.

NHS England has identified Clinical and Programme oversight resource to be active during reorganisation, with a lead programme management resource to support prioritised national workstreams.

The programme to date has prioritised reviews of the differential impact of liver disease in relation to health inequalities and deprivation. Examples include evidence of liver-related premature mortality being 4.8 times higher in the most deprived areas, 86% of liver disease deaths, which have increased by 400% since 1970, being related to alcohol harms, South Asian communities being at a higher risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and type 2 diabetes and MASLD disproportionately affecting the most deprived communities.

The transformation of the liver services programme includes a number of workstreams including awareness, early identification, and treatment of liver disease, and these will benefit people in these communities. Geographically specific data is available to local commissioners to assist them with focusing their work on deprivation and inequalities, to support their prioritisation.

The resource for transforming liver services sits with integrated care boards, who will consider local need and the actions to progress alongside other clinical priorities.

The national team’s role has been to bring together relevant stakeholders to co-ordinate, influence and share learning to support local transformation.

NHS England has identified Clinical and Programme oversight resource to be active during reorganisation, with a lead programme management resource to support prioritised national workstreams.

The programme to date has prioritised reviews of the differential impact of liver disease in relation to health inequalities and deprivation. Examples include evidence of liver-related premature mortality being 4.8 times higher in the most deprived areas, 86% of liver disease deaths, which have increased by 400% since 1970, being related to alcohol harms, South Asian communities being at a higher risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and type 2 diabetes and MASLD disproportionately affecting the most deprived communities.

The transformation of the liver services programme includes a number of workstreams including awareness, early identification, and treatment of liver disease, and these will benefit people in these communities. Geographically specific data is available to local commissioners to assist them with focusing their work on deprivation and inequalities, to support their prioritisation.

The resource for transforming liver services sits with integrated care boards, who will consider local need and the actions to progress alongside other clinical priorities.

The national team’s role has been to bring together relevant stakeholders to co-ordinate, influence and share learning to support local transformation.

NHS England has identified Clinical and Programme oversight resource to be active during reorganisation, with a lead programme management resource to support prioritised national workstreams.

The programme to date has prioritised reviews of the differential impact of liver disease in relation to health inequalities and deprivation. Examples include evidence of liver-related premature mortality being 4.8 times higher in the most deprived areas, 86% of liver disease deaths, which have increased by 400% since 1970, being related to alcohol harms, South Asian communities being at a higher risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and type 2 diabetes and MASLD disproportionately affecting the most deprived communities.

The transformation of the liver services programme includes a number of workstreams including awareness, early identification, and treatment of liver disease, and these will benefit people in these communities. Geographically specific data is available to local commissioners to assist them with focusing their work on deprivation and inequalities, to support their prioritisation.

Liver health and liver cancer remain a priority for the National Health Service. NHS England has established a liver transformation programme focussing on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease, such as cirrhosis, including patient pathways relating to metabolic associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH).

Non-alcoholic cirrhosis increases the risk of liver cancer, and to identify more liver cancers earlier, minimum standards for liver cancer surveillance have been rolled out nationally and Cancer Alliances continue to invest cancer service development funding in local liver cancer surveillance programmes. As set out in the National Cancer Plan, the community liver health checks programme will continue to offer fibroscans to people with cirrhosis and fatty liver disease, to proactively identify 4,000 patients each year at high-risk of developing hepatocellular carcinoma.

The NHS Cancer Programme continues to reach out into the communities worst affected by liver disease through the Community Liver Health Checks programme, to proactively identify people suitable for liver cancer surveillance. Many of the patients identified by this route also receive lifestyle advice and support which aims to reduce future cancer risk.

NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing National Institute for Health and Care Excellence appraisal process.

Liver health and liver cancer remain a priority for the National Health Service. NHS England has established a liver transformation programme focussing on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease, such as cirrhosis, including patient pathways relating to metabolic associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH).

Non-alcoholic cirrhosis increases the risk of liver cancer, and to identify more liver cancers earlier, minimum standards for liver cancer surveillance have been rolled out nationally and Cancer Alliances continue to invest cancer service development funding in local liver cancer surveillance programmes. As set out in the National Cancer Plan, the community liver health checks programme will continue to offer fibroscans to people with cirrhosis and fatty liver disease, to proactively identify 4,000 patients each year at high-risk of developing hepatocellular carcinoma.

The NHS Cancer Programme continues to reach out into the communities worst affected by liver disease through the Community Liver Health Checks programme, to proactively identify people suitable for liver cancer surveillance. Many of the patients identified by this route also receive lifestyle advice and support which aims to reduce future cancer risk.

NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing National Institute for Health and Care Excellence appraisal process.

Services to manage and treat patients with liver disease are commissioned at a local level and are considered alongside other healthcare priorities. Specific investment in services is decided locally, reflecting local population need.

The liver transformation programme has developed a data pack for regional commissioners using public health Fingertips data, to raise awareness of incidence and prevalence of liver disease. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions.

National Institute for Health and Care Excellence (NICE) guidelines recommend that patients and/or the families of people with cystic fibrosis are provided with the relevant information and the opportunity for discussion with clinicians on topics that include their diagnosis, monitoring of their condition, management options, and existing or possible complications that could relate to comorbidities like liver disease. NICE guidelines are available at the following link:

https://www.nice.org.uk/guidance/ng78

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Liver disease is a broad term for several conditions affecting the liver and pancreas and the Government is taking decisive action to tackle ill health and shift the focus on diseases such as liver disease from treatment to prevention.

The most prevalent cause of liver-related ill health and death is alcohol-related liver disease. From 2026/27, all alcohol and drug treatment and recovery funding will be channelled through the Public Health Grant, with ringfenced funding in which Blackpool Council will receive £4,554,578 in 2026/27 and indicative totals of £4,647,350 and £4,737,845 for 2027/28 and 2028/29 respectively. The Department has also published the United Kingdom’s first clinical guidelines on alcohol treatment which include guidance on early identification of liver disease and treating alcohol dependence in people with liver disease. To help people make healthier choices about alcohol we are making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information.

Locally, Blackpool Teaching Hospital’s Liver Service has recently achieved micro‑elimination of hepatitis C, with all drug and alcohol services across Lancashire now declared micro‑eliminated. The region’s Liver Health Check Team supports earlier detection of liver disease by referring at‑risk individuals, including those with high body mass index, diabetes, or high alcohol consumption for community fibroscans available in general practices (GPs), community venues, and via mobile units.

NHS England’s liver transformation programme focusses on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease and has developed a data pack for regional commissioners using the Department’s Fingertips data to support this. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions. The National Institute for Health and Care Excellence is assessing new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), the broader term for fat buildup of the liver, which metabolic dysfunction-associated steatohepatitis (MASH) falls under. This includes resmetirom and semaglutide. Outputs and recommendations are expected to be published mid-2026.

As part of our 10-Year Health Plan, we are improving diets, reducing physical inactivity, and creating healthier environments so that fewer people reach the point of needing treatment for diseases such as MASH. This includes updating the standards behind the advertising and promotions restrictions on ‘less healthy’ food and drink, requiring all large food businesses to report against standardised metrics on the healthiness of food sales and getting millions moving more through our national movement campaign.

Liver disease is a broad term for several conditions affecting the liver and pancreas and the Government is taking decisive action to tackle ill health and shift the focus on diseases such as liver disease from treatment to prevention.

The most prevalent cause of liver-related ill health and death is alcohol-related liver disease. From 2026/27, all alcohol and drug treatment and recovery funding will be channelled through the Public Health Grant, with ringfenced funding in which Blackpool Council will receive £4,554,578 in 2026/27 and indicative totals of £4,647,350 and £4,737,845 for 2027/28 and 2028/29 respectively. The Department has also published the United Kingdom’s first clinical guidelines on alcohol treatment which include guidance on early identification of liver disease and treating alcohol dependence in people with liver disease. To help people make healthier choices about alcohol we are making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information.

Locally, Blackpool Teaching Hospital’s Liver Service has recently achieved micro‑elimination of hepatitis C, with all drug and alcohol services across Lancashire now declared micro‑eliminated. The region’s Liver Health Check Team supports earlier detection of liver disease by referring at‑risk individuals, including those with high body mass index, diabetes, or high alcohol consumption for community fibroscans available in general practices (GPs), community venues, and via mobile units.

NHS England’s liver transformation programme focusses on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease and has developed a data pack for regional commissioners using the Department’s Fingertips data to support this. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions. The National Institute for Health and Care Excellence is assessing new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), the broader term for fat buildup of the liver, which metabolic dysfunction-associated steatohepatitis (MASH) falls under. This includes resmetirom and semaglutide. Outputs and recommendations are expected to be published mid-2026.

As part of our 10-Year Health Plan, we are improving diets, reducing physical inactivity, and creating healthier environments so that fewer people reach the point of needing treatment for diseases such as MASH. This includes updating the standards behind the advertising and promotions restrictions on ‘less healthy’ food and drink, requiring all large food businesses to report against standardised metrics on the healthiness of food sales and getting millions moving more through our national movement campaign.

The Office for Health Improvement and Disparities (OHID) ceased to update non-alcoholic fatty liver disease (NAFLD) hospital admissions rates and premature deaths, in people aged under 75 years old, on the Fingertips profiles in December 2025. These only measure the most serious, and a small proportion of cases of the disease, and did not relate directly to the disease prevalence, level of disease, within the population.

These are not accurate measures of NAFLD within the population, a condition that is linked to obesity and which can be prevented and treated at early stages with healthy lifestyle changes. The latest reported data for England showed that 345 deaths due to NAFLD in 2023 and 3,126 hospital admissions in 2022/23. There is no data measuring the prevalence of NAFLD.

The decision to cease updates occurred after a process that examined data usage, potential duplication, and relative impact of the indicator on disease prevention and monitoring.

We concluded that the cessation of publication of these indicators would have limited impact on our efforts to monitor trends on the level of these diseases within the population.

Alternative data sources to monitor the population risk of this condition include measures of obesity, physical activity, and nutrition which continue to be published by OHID.

Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims wherever possible to issue draft guidance on new medicines close to the time of licensing. The NHS in England is legally required to fund drugs recommended by NICE, usually within three months of final guidance.

NICE is currently evaluating potential new treatments for metabolic dysfunction-associated steatohepatitis (MASH) in anticipation of the medicines being granted a marketing authorisation by the Medicines and Healthcare products Regulatory Agency with guidance expected later this year. NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing NICE appraisal process.

The Department and NHS England will continue to work to ensure that, once approved, effective new treatments for fatty liver disease are introduced in a way that is fair, affordable, and which protects the wider NHS, while ensuring that patients with the greatest clinical need are able to benefit as quickly as possible.

Locally, the Hampshire and Isle of Wight Integrated Care Board (ICB) is implementing the NHS Long Term Plan’s commitments on earlier diagnosis of liver diseases. This includes expanding access to non-invasive testing in primary care and community diagnostic centres delivering liver function tests and fibroscans in community environments. The ICB is also promoting consistent use of risk stratification tools, improving care navigation into specialist hepatology services via advice and guidance, and strengthening data infrastructure so systems can better target those at highest risk.

Nationally, NHS England has commenced a programme of work on the transformation of liver services led by the Hepatobiliary and Pancreas Clinical Reference Group (HPB CRG). The HPB CRG is working with partners to co-produce resources to raise public knowledge and awareness of all forms of liver disease.

The HPB CRG is also aiming to improve the early diagnosis and intervention through developing evidence-based best-practice pathways for both primary care and referral to secondary care services.

Data on hospital admission rates for metabolic dysfunction-associated steatotic liver disease (MASLD), of which metabolic dysfunction–associated steatohepatitis is a stage in some cases, is available at the Department’s Fingertips website, and can be used by regional commissioners to monitor the incidence of the disease. This data is available at county, but not constituency level. Further information is available at the following link:

https://fingertips.phe.org.uk/profile/liver-disease/data#page/1/gid/8000063/pat/15/par/E92000001/ati/502/are/E10000024/iid/90931/age/1/sex/4/cat/-1/ctp/-1/yrr/3/cid/4/tbm/1/page-options/car-do-0

Recognising the increasing burden that liver disease has on the population, NHS England has initiated a liver transformation programme. This focusses on awareness, prevention, diagnosis, detection and treatment of all forms of liver disease. The liver transformation programme has developed a data pack for regional commissioners using the Fingertips data mentioned above, to raise awareness of incidence of liver disease. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions.

The Government is taking decisive action to tackle ill health and shift the focus on diseases such as MASLD from treatment to prevention. As part of our 10-Year Health Plan, we are improving diets, reducing physical inactivity, and creating healthier environments so that fewer people reach the point of needing treatment. This includes updating the standards behind the advertising and promotions restrictions on ‘less healthy’ food and drink and requiring all large food businesses to report against standardised metrics on the healthiness of food sales. We will also get millions moving more through our national movement campaign and We are committed to taking crucial steps to help people make healthier choices about alcohol, including making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information.

Newly licensed medicines are appraised by the National Institute for Health and Care Excellence (NICE), which is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims wherever possible to issue draft guidance on new medicines close to the time of licensing. The NHS in England is legally required to fund drugs recommended by NICE, usually within three months of final guidance.

NICE is currently evaluating potential new treatments for metabolic dysfunction-associated steatohepatitis (MASH) in anticipation of the medicines being granted a marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) with guidance expected later this year. NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing NICE appraisal process.

The Department and NHS England will continue to work to ensure that, once approved, effective new treatments for fatty liver disease are introduced in a way that is fair, affordable and protects the wider NHS, while ensuring that patients with the greatest clinical need are able to benefit as quickly as possible.

Non-alcoholic fatty liver disease is now commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), although the terms are still often used interchangeably.

While the Department has not had any recent discussions with medical professionals about care for people with MASLD, NHS England has recently commenced a programme for the transformation of liver services. This programme is being led by the NHS England Hepatobiliary and Pancreas Clinical Reference Group (HPB CRG). HPB CRG is working with partners to co-produce resources to raise public knowledge and awareness of all forms of liver disease. In time, this may include incorporating liver health checks into the NHS Making Every Contact Count and NHS Health Checks initiatives.

The HPB CRG is also aiming to improve early diagnosis and intervention through developing evidence-based best-practice pathways for both primary care and referral to secondary care services. The HPB CRG is looking at access and equity of access to diagnostic tests across England and exploring the applicability of automated Fib4 tests and Intelligent Liver Function Testing, potentially utilising community diagnostic centres.

The British Society for Gastroenterology is currently updating its pathways and guidance for MASLD for both primary and secondary care, diagnostics, and treatment, which we anticipate will be published soon. There are also a number of ongoing National Institute for Health and Care Excellence assessments looking at new treatments for MASLD, including Resmetirom and Semaglutide. Outputs and recommendations are expected to be published in mid-2026.

Clinical teams also have access to NHS England’s Getting it Right First Time Advice and Guidance toolkit and templates for gastroenterology, which feature advice on managing abnormal liver function tests and MASLD. These templates enable general practitioners to seek timely advice from secondary care specialists, helping to reduce unnecessary delays.

Non-alcoholic fatty liver disease is now commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), although the terms are still often used interchangeably.

While the Department has not had any recent discussions with medical professionals about care for people with MASLD, NHS England has recently commenced a programme for the transformation of liver services. This programme is being led by the NHS England Hepatobiliary and Pancreas Clinical Reference Group (HPB CRG). HPB CRG is working with partners to co-produce resources to raise public knowledge and awareness of all forms of liver disease. In time, this may include incorporating liver health checks into the NHS Making Every Contact Count and NHS Health Checks initiatives.

The HPB CRG is also aiming to improve early diagnosis and intervention through developing evidence-based best-practice pathways for both primary care and referral to secondary care services. The HPB CRG is looking at access and equity of access to diagnostic tests across England and exploring the applicability of automated Fib4 tests and Intelligent Liver Function Testing, potentially utilising community diagnostic centres.

The British Society for Gastroenterology is currently updating its pathways and guidance for MASLD for both primary and secondary care, diagnostics, and treatment, which we anticipate will be published soon. There are also a number of ongoing National Institute for Health and Care Excellence assessments looking at new treatments for MASLD, including Resmetirom and Semaglutide. Outputs and recommendations are expected to be published in mid-2026.

Clinical teams also have access to NHS England’s Getting it Right First Time Advice and Guidance toolkit and templates for gastroenterology, which feature advice on managing abnormal liver function tests and MASLD. These templates enable general practitioners to seek timely advice from secondary care specialists, helping to reduce unnecessary delays.

NHS Blood and Transplant (NHSBT) is the organisation responsible for organ donation in the United Kingdom, they also manage the NHS Organ Donor Register and National Transplant Register.

NHSBT publishes an annual Organ and Tissue Donation and Transplantation Activity Report which gives a comprehensive update about organ donors, transplant waiting lists, and transplant activity for the UK for the latest financial year. Section 8.4 of the report details liver transplant activity, data on transplants by country/National Health Service region of residence, in Table 8.8, and by transplant centre, in Table 8.9. NHSBT Annual Activity reports are available at the following link:

https://www.odt.nhs.uk/statistics-and-reports/annual-activity-report/